Ligand Pharma (LGND) Tops Q2 EPS by 21c, Beats on Revenues; Guides FY17 Revenues Above Consensus
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/25/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
| LIGAND PHARMA (NASDAQ: LGND) | Delayed: 303.53 -4.29 (1.39%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $307.82 | 52 Week High | $139.79 | |||
| Open | $307.82 | 52 Week Low | $82.07 | |||
| Day High | $313.28 | P/E | 705.88 | |||
| Day Low | $302.37 | EPS | $0.43 | |||
| Volume | 366,588 | |||||
